Dr. Ravaud has received consulting fees, speaking fees, and/or honoraria from Servier, Roche, Daiichi Sankyo, Pfizer, Sanofi, Schering-Plough, and Almirall (less than $10,000 each).
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Osteoarthritis
You have full text access to this OnlineOpen article
Effect of hyaluronic acid in symptomatic hip osteoarthritis: A multicenter, randomized, placebo-controlled trial†
Article first published online: 26 FEB 2009
DOI: 10.1002/art.24301
Copyright © 2009 by the American College of Rheumatology
Additional Information
How to Cite
Richette, P., Ravaud, P., Conrozier, T., Euller-Ziegler, L., Mazières, B., Maugars, Y., Mulleman, D., Clerson, P. and Chevalier, X. (2009), Effect of hyaluronic acid in symptomatic hip osteoarthritis: A multicenter, randomized, placebo-controlled trial. Arthritis & Rheumatism, 60: 824–830. doi: 10.1002/art.24301
- †
ClinicalTrials.gov identifier: NCT00330135.
- ‡
Dr. Ravaud has received consulting fees, speaking fees, and/or honoraria from Servier, Roche, Daiichi Sankyo, Pfizer, Sanofi, Schering-Plough, and Almirall (less than $10,000 each).
- §
Dr. Conrozier has received consulting fees, speaking fees, and/or honoraria from Genome and Bristol-Myers Squibb (less than $10,000 each) and from Pfizer and Smith & Nephew (more than $10,000 each).
- ¶
Dr. Clerson has received consulting fees, speaking fees, and/or honoraria from Daiichi Sankyo, Actelion, Janssen, Takeda, and Bayer Schering (more than $10,000 each).
- ‖
Dr. Chevalier has received consulting fees, speaking fees, and/or honoraria from Expanscience, Pfizer, Genzyme, Servier, Sankyo, Rottapharma, and Fidia (less than $10,000 each).
Publication History
- Issue published online: 26 FEB 2009
- Article first published online: 26 FEB 2009
- Manuscript Accepted: 7 NOV 2008
- Manuscript Received: 16 MAY 2008
Funded by
- Daiichi Sankyo France
- Abstract
- Article
- References
- Cited By
Abstract
Objective
To evaluate the efficacy and tolerability of a single intraarticular (IA) injection of hyaluronic acid (HA) for the treatment of hip osteoarthritis (OA).
Methods
A multicenter, randomized, parallel-group, placebo-controlled trial was conducted over 3 months. Patients (older than 30 years) with symptomatic hip OA (pain score of >40 mm on a visual analog scale [VAS]) and a Kellgren/Lawrence grade of 2 or 3 were randomly assigned to receive 1 fluoroscopically guided IA injection of HA (2.5 ml) or placebo (2.5 ml). Patients were followed up for 3 months. The main outcome measure was pain score on a VAS (100 mm) at month 3 compared with baseline. Secondary outcome measures were the proportion of responders defined by Osteoarthritis Research Society International criteria; Western Ontario and McMaster Universities Osteoarthritis Index subscores for pain, stiffness, and disability; and patient and physician global assessment. Randomization was computer generated. HA and placebo preparations were placed in numbered identical containers, and syringes were covered with masking tape. Physicians assessing outcomes were blinded with regard to group assignment.
Results
Eighty-five patients were randomized to the HA group (n = 42) or placebo group (n = 43). Baseline characteristics were similar between the 2 groups. At 3 months, the decrease in pain score did not differ between the HA and placebo groups in the intent-to-treat analysis (mean ± SD decrease 7.8 ± 24.9 mm with HA versus 9.1 ± 27.4 mm with placebo; P = 0.98). The responder rates were 33.3% and 32.6% in the HA and placebo groups, respectively (P = 0.94). Other secondary end points did not differ between the groups, nor did use of rescue medication or frequency of adverse events.
Conclusion
Our findings indicate that a single IA injection of HA is no more effective than placebo in treating the symptoms of hip OA.